Study wrapper · #1005
Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.
Editor's note
This consensus statement synthesizes retrospective observational studies examining whether semaglutide and other GLP-1 receptor agonists are associated with non-arteritic anterior ischemic optic neuropathy. The evidence is mixed: some studies report a small possible increase in risk while others find none, and the absolute risk is described as low. It is a useful safety-signal reference, with the authors emphasizing shared decision-making rather than a definitive causal link.
Plain-language abstract
Two major eye-care societies issued a consensus statement on the possible association between GLP-1 receptor agonists such as semaglutide and a form of optic-nerve damage called NAION. They note the evidence comes mainly from retrospective observational data, that findings are inconsistent, and that the overall risk appears low.